Philippe Beuzeboc

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 740 citations

Medicine, Oncology, Urology +16

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2021 · 533 citations · Full text

Medicine, Oncology, Pharmacology +13

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology · 2015 · 462 citations

Medicine, Oncology, Urology +17

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles et al. · New England Journal of Medicine · 2023 · 462 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

Vincent Launay‐Vacher, Stéphane Oudard, Nicolas Janus et al. · Cancer · 2007 · 455 citations

Pharmacy, Oncology, Pharmacotherapy +17